Reuters logo
BRIEF-Syros says on track to begin Phase 1 trial of SY-1365 in Q2
April 3, 2017 / 12:20 PM / 6 months ago

BRIEF-Syros says on track to begin Phase 1 trial of SY-1365 in Q2

April 3 (Reuters) - Syros Pharmaceuticals Inc:

* Syros Pharmaceuticals Inc - new data demonstrate SY-1365 inhibits tumor growth in In Vivo models of triple negative breast cancer

* Syros Pharmaceuticals Inc - new data demonstrate sy-1365 inhibits tumor growth in in vivo models of triple negative breast cancer

* Syros Pharma - new data show sy-1365 has anti-proliferative activity in additional cancer cells, including ovarian and small cell lung cancers

* Syros Pharmaceuticals Inc - on track to begin a Phase 1 clinical trial of SY-1365 in Q2 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below